shutterstock_619031537_castleski-1

Castleski / Shutterstock.com

23 June 2021Big PharmaAlex Baldwin

Pharma company fails to block €140m licence payment

Taiwanese pharmaceutical company PharmaEssentia Corporation (PEC) has failed to convince a district court judge to throw out a €140 million award to AOP Orphan Pharmaceuticals (AOP).

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biogen blocking bid rejected; signs $2.4bn deal

28 February 2020 The US Court of Appeals for the Federal Circuit has rejected Biogen’s bid to block a bioequivalent version of its multiple sclerosis drug, pending an appeal against a lower court’s ruling.

Amgen successfully blocks sale of Sandoz’s Zarxio biosimilar

7 May 2015 The US Court of Appeals for the Federal Circuit has blocked US sales of Sandoz’s Zarxio, the biosimilar version of Amgen’s Neupogen, an injection used to prevent infection in patients undergoing chemotherapy.

More on this story

Biogen blocking bid rejected; signs $2.4bn deal

28 February 2020 The US Court of Appeals for the Federal Circuit has rejected Biogen’s bid to block a bioequivalent version of its multiple sclerosis drug, pending an appeal against a lower court’s ruling.

Amgen successfully blocks sale of Sandoz’s Zarxio biosimilar

7 May 2015 The US Court of Appeals for the Federal Circuit has blocked US sales of Sandoz’s Zarxio, the biosimilar version of Amgen’s Neupogen, an injection used to prevent infection in patients undergoing chemotherapy.

More on this story

Biogen blocking bid rejected; signs $2.4bn deal

28 February 2020 The US Court of Appeals for the Federal Circuit has rejected Biogen’s bid to block a bioequivalent version of its multiple sclerosis drug, pending an appeal against a lower court’s ruling.

Amgen successfully blocks sale of Sandoz’s Zarxio biosimilar

7 May 2015 The US Court of Appeals for the Federal Circuit has blocked US sales of Sandoz’s Zarxio, the biosimilar version of Amgen’s Neupogen, an injection used to prevent infection in patients undergoing chemotherapy.

More features

LSPN: In-house ‘chess game’ is the same, but the rules have changed

Life sciences leaders recognised at LSPN Awards USA 2025

UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body

LSPN: Counsel grapple with AI’s impact on training and critical thinking

'Nothing can stand in the way of our work': Ukraine resumes IP system

LSPN: Trump's policy storm causing chaos and confusion

Taylor Wessing expands in Europe with Paris team

LSPN: Using ‘the patentee’s friend’ in Section 112 claims